Начало・Списък с акции・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Затворен

СекторЗдравеопазване

107.43 1.89

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

104.37

Максимум

107.87

Ключови измерители
By Trading Economics
Приходи	18M -69M
Продажби	32M 34M
EPS	-0.71
Марж на печалбата	-201.467
Служители	253
EBITDA	18M -67M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+23.38% upside

Дивиденти
By Acuity
Следващи печалби	3.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.2B 8.3B
Предишно отваряне	105.54
Предишно затваряне	107.43

Настроения в новините

By Acuity

50%

151 / 340 Класиране в Healthcare

Kymera Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.08.2026 г., 19:56 ч. UTC

Kymera Therapeutics Inc shares are lower today, trading near the lower end of their one-month range amid broader market dynamics and inflationary concerns.

5.08.2026 г., 20:02 ч. UTC

Social Media

News

Kymera Therapeutics reported a narrower net loss of $61.21 million for Q2 2026, driven by increased collaboration revenue and a price target raise from Stifel to $132.

4.08.2026 г., 20:04 ч. UTC

Correlated Moves

Kymera Therapeutics Inc is rising in Tuesday's session, reflecting bullish sentiment in the biotechnology sector amid a broader market uptrend.

3.08.2026 г., 19:46 ч. UTC

News

Kymera Therapeutics Inc shares are lower amid volatility, following Dimensional Fund Advisors LP's 5% stake reduction and broader market trends in biotechnology.

31.07.2026 г., 20:06 ч. UTC

Correlated Moves

Kymera shares lower amid SPDR S&P Biotech ETF decline.

30.07.2026 г., 19:39 ч. UTC

Kymera Therapeutics Inc shares are higher during Thursday's session, with no specific news identified to explain the price action amid broader market trends.

29.07.2026 г., 19:32 ч. UTC

Macro Event

Kymera Therapeutics shares are higher as the Federal Reserve maintains rates at 3.50%–3.75%. Investors monitor inflation trends and their impact on future policy.

28.07.2026 г., 17:42 ч. UTC

News

Social Media

Shares lower despite Guggenheim's price target increase to $135.

27.07.2026 г., 21:03 ч. UTC

News

Kymera Therapeutics shares are lower in after-market hours following the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD.

24.07.2026 г., 18:46 ч. UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21.07.2026 г., 19:16 ч. UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20.07.2026 г., 22:16 ч. UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.

Сравнение с други в отрасъла

Ценова промяна

Kymera Therapeutics Inc Прогноза

Ценова цел

By TipRanks

23.38% нагоре

12-месечна прогноза

Среден 131.29 USD 23.38%

Висок 155 USD

Нисък 112 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Kymera Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

17 ratings

Купи

Задържане

Продай

Според 17 анализатори, дали борсови рейтинги на Kymera Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

151 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.